- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05604274
Longitudinal Monitoring of Stool Characteristics
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In patients with cirrhosis and healthy controls to determine the utility of an App to classify BSS compared to assessment made by the patients themselves using the BSS and correlate these with other stool characteristics and gut microbiota.
Patients with cirrhosis are often treated with lactulose, that needs monitoring of bowel movement numbers and is overall not acceptable to a majority of patients. The estimation of this number is not completely accurate and varies day by day. In addition, recent work has shown that consistency of the stools with the Bristol Stool Scale (BSS) may be another important metric to determine who will respond well to lactulose versus not.
In addition to the issue of remembering exact details of bowel movement frequency, it is often hard for patients, especially with HE, to remember details of their daily function. Additionally, insight into the impact of the disease. Traditionally, patients assess stool form and consistency using the Bristol stool score and chart, which classifies stool into one of seven types. A challenge with this is that the assessment is subjective and may vary from patient to patient. This is seen in patients without cognitive dysfunction such as those with irritable bowel syndrome (IBS). Therefore, it is likely that patients with cirrhosis, who often have cognitive dysfunction, could be worse in estimating stool consistency. In addition, microbiome structure and function, which is often dependent on stool consistency may be measured differently based on personal vs app-generated BSS values.
Thus, method to better estimate stool characteristics, which could better inform patient management through telemedicine is needed. Aim: Monitor patients using a mobile health application designed for monitoring and assessing patients with digestive diseases.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Recruiting
- Hunter Holmes McGuire VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
For cirrhosis subjects must meet all of the following inclusion criteria to be eligible:
- Male and female subjects aged ≥ 18 years.
- Cirrhosis
- Able and willing to voluntarily complete the informed consent process
- Familiar with smartphone technology
- Available for and agree to all study procedures, including taking the pictures of the stool and collection of stool
For controls :
- Male and female subjects aged ≥ 18 years.
- Absence of chronic diseases requiring prescription medications
- Able and willing to voluntarily complete the informed consent process
- Familiar with smartphone technology
- Available for and agree to all study procedures, including taking the pictures of the stool and collection of stool for microbiome analysis
Exclusion Criteria:
Subjects with cirrhosis meeting any of the following criteria are not eligible for study enrollment:
- Unclear diagnosis of cirrhosis
- History of liver transplant
- For those on lactulose, they need to be on it for at least 2 weeks
- Unfamiliar with smartphones
- Apart from chronic liver disease, any acute or chronic medical, surgical, psychiatric, or social condition including history of cerebrovascular disease (stroke, transient ischemic attack) or dementia, that may increase the subject risk associated with study participation, compromise adherence to study procedures and requirements, confound interpretation of the results, and, in the judgment of the investigator, make the subject inappropriate for enrollment.
For healthy controls
- Any chronic disease requiring prescription medications
- Unfamiliar with smartphones
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy controls
|
App to monitor stool consistency and symptoms
|
Patients with cirrhosis on lactulose
|
App to monitor stool consistency and symptoms
|
Patients with cirrhosis on rifaximin
|
App to monitor stool consistency and symptoms
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
App use comfort measured by survey
Time Frame: 2 weeks
|
A survey designed to assess acceptability of this App at baseline and at 2 weeks; higher score=good
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alpha diversity using Shannon index of microbiome
Time Frame: 2 weeks
|
we will test association of the stool characteristics with microbial characteristics
|
2 weeks
|
Bristol stool scale by subjects
Time Frame: 2 weeks
|
we will test association of the stool characteristics gauged through the App versus the Bristol stool scale by subjects
|
2 weeks
|
Quality of life using Sickness Impact Profile
Time Frame: 2 weeks
|
we will test association of the stool characteristics with quality of life; higher=good
|
2 weeks
|
Cognitive testing using PHES
Time Frame: 2 weeks
|
we will test association of the stool characteristics with PHES values; higher=good
|
2 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BAJAJ033
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis, Liver
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on App to monitor stool consistency and symptoms
-
University of TennesseeUniversity of Tennessee West Cancer CenterCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Odense University HospitalRigshospitalet, Denmark; Danish Cancer SocietyRecruiting
-
University of TennesseeUniversity of Tennessee West Cancer CenterCompleted
-
Quanovate Tech Inc.Completed
-
M.D. Anderson Cancer CenterWithdrawnMalignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
Karolinska InstitutetResearch Institutes of Sweden (RISE)CompletedQuality of Life | mHealth | Mobile Applications | Lifestyle | AdultsSweden
-
Universidad Complutense de MadridFUNDACION PARA LA INVESTIGACION HOSPITAL CLINICO SAN CARLOSCompleted
-
University Hospital, MontpellierRheonovaRecruitingChronic Obstructive Pulmonary DiseaseFrance
-
Royal College of Surgeons, IrelandNot yet recruitingStress Psychological | Overall Wellness | No Disease or Condition is Being Studied